Dr. Suliman has served as a member of the Ultragenyx Board since January 2019. She is a physician, drug developer and dealmaker with over 25 years of experience building and transforming small and large biopharmaceutical companies.
She currently serves as Chief Executive Officer at ReCode Therapeutics, a position she has held since January 2022. Prior to becoming CEO of ReCode Therapeutics, she served as president and chief operating officer of Alector, a leading immuno-neurology and immuno-oncology company where she played a critical role growing, scaling, raising capital and advancing a late-stage development pipeline. Prior to Alector, she served as senior vice president, corporate development and strategy at Theravance Biopharma from 2017 to 2019, where she helped deliver a $1B profit sharing partnership with Janssen for the company’s lead JAK inhibitor program.
Prior to Theravance, Dr. Suliman was vice president and global head, immunology, infectious diseases and specialty care at Roche from 2015 to 2017. Dr. Suliman worked for Genentech as a group leader and project team leader in the R&D Portfolio Management and Operations Group from 2010 to 2015, where she oversaw an early development portfolio of more than 30 programs across multiple therapeutic areas. She held various management roles of increasing responsibility at Gilead Sciences, Inc. between 2005 and 2010 and played a significant role in forward-integrating Gilead into new therapeutic areas through M&A. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners, advising numerous public and private companies on buy- and sell-side transactions.
She was named as one of the 2017 Fiercest Women in Life Sciences and as one of the National Diversity Council’s Power 50 in 2021 (Most Influential Women in Business). In addition to serving as an independent director on the Board of Directors of Ultragenyx, she is also on the ReCode Therapeutics and 10x Genomics boards. Dr. Suliman received her M.D. (MB, ChB) from the University of Cape Town Medical School, South Africa, and holds an MBA, with distinction, and M.Phil. degrees from Oxford University, where she was a Rhodes Scholar.
How do I contact Shehnaaz Suliman?
Has Shehnaaz Suliman been buying or selling shares of Alector?
Shehnaaz Suliman has not been actively trading shares of Alector over the course of the past ninety days. Most recently, Shehnaaz Suliman sold 75,000 shares of the business's stock in a transaction on Monday, December 13th. The shares were sold at an average price of $21.24, for a transaction totalling $1,593,000.00. Learn More on Shehnaaz Suliman's trading history.
Who are Alector's active insiders?
Are insiders buying or selling shares of Alector?
During the last year, insiders at the sold shares 13 times. They sold a total of 162,311 shares worth more than $875,829.44. The most recent insider tranaction occured on September, 3rd when CFO Marc Grasso sold 7,297 shares worth more than $35,609.36. Insiders at Alector own 9.1% of the company.
Learn More about insider trades at Alector. Information on this page was last updated on 9/3/2024.
